Clinical trials: cyclosporine
Dry Eye Disease
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
Primary Objectives: To compare the efficacy of cenegermin vs vehicle in Schirmer I test (without anaesthesia) > 10 mm/5 min at Week 4 by testing the superiority.
- Trial name
- PROTEGO-2 (NCT05136170)
- Testing
- Cenegermin, Vehicle
- Where
- 10 sites in United States, Italy
- Volunteers
- 85 people
- Sponsor
- Dompé Farmaceutici S.p.A
Systemic Sclerosis, Arthritis
Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis
Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of the skin and several internal organs.
- Trial name
- NCT01834157
- Where
- 33 sites in Belgium, Croatia and 12 more
- Volunteers
- 160 people
- Sponsor
- Prof. Laszlo Czirjak
Hospitalization, All Conditions
New Approaches for Evaluating the Interchangeability of Reference Materials and Quality Controls (COMET-MPL)
Medical biology tests are essential to clinical decision-making. The European Regulation on in vitro diagnostic medical devices (EU/2017/746) requires metrological traceability of the values assigned to calibrators and quality…
- Trial name
- COMET-MPL (NCT07173114)
- Where
- 2 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Montpellier
Myelodysplastic Syndrome, Hodgkin's Lymphoma
Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD)…
- Conditions
- Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia
- Trial name
- NCT00520130
- Testing
- Rituximab, Cyclosporine, Allogenic stem cell transplant (ASCT)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Cancer Institute (NCI)
Maintenance Renal Transplantation
Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,
The aim of this study is to evaluate if the addition of EC-MPS to CsA-ME allows the safe withdrawal of the concomitant corticosteroid therapy in long-term maintenance renal allograft recipients.
- Trial name
- NCT00239057
- Testing
- Enteric-Coated Mycophenolate Sodium
- Volunteers
- 23 people
- Sponsor
- Novartis
Renal Function, Liver Transplant
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
This study was designed to assess the evolution of renal function and to collect efficacy, safety, and tolerability data of everolimus in co-exposure with reduced CNI in paediatric liver transplant recipients.
- Trial name
- NCT01598987
- Testing
- Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.
- Where
- 32 sites in United States, Australia and 10 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris.
- Trial name
- NCT00050648
- Testing
- Daclizumab, Cyclosporine, cyclosporine and Daclizumab
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Rockefeller University
Graft Versus Host Disease
Everolimus in Combination With Cyclosporine A and Prednisolone for the Treatment of Graft Versus Host Disease
The present protocol is a dose-finding and toxicity study in preparation of a randomised study comparing current standard treatment CSA/prednisolone with the new combination CSA/prednisolone/everolimus.
- Trial name
- NCT00373815
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital Tuebingen
Delayed Graft Function, Kidney Transplant
Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
The purpose of this study is to evaluate the safety and efficacy of conversion from a calcineurin inhibitor (tacrolimus or cyclosporine) immunosuppression therapy to Nulojix® (belatacept) immunosuppression therapy in patients…
- Trial name
- NCT01837043
- Testing
- Belatacept, Calcineurin Inhibitor
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Nair, Vinay, D.O.
Dry Eye Disease With Severe Keratitis
Autologous Plasma Rich in Growth Factors for Severe Dry Eye Disease
The goal of this clinical trial is to evaluate the change in dry eye symptoms after the treatment with Plasma Rich in Growth Factors (PRGF) in patients with severe dry eye.
- Trial name
- PRGF (NCT07773740)
- Testing
- PRGF, Balanced Salt Solution (BSS®)
- Volunteers
- 100 people
- Sponsor
- Gladys Lucia Silva Linares
Dry Eye
The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface
This study will test that hypothesis that topical administration of the FDA approved immunomodulatory agent cyclosporin A emulsion will minimize irritation and ocular surface disease that results from a short term low humidity…
- Trial name
- CsA (NCT02199964)
- Testing
- Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Baylor College of Medicine
Dry Eye, Contact Lens Complication
Cyclosporine and Intense Pulsed Light for Dry Eye in Contact Lens Users
In this study, two treatments typically used for dry eye disease will be tried for contact lens users to see if their symptoms when they use their contact lenses get better.
- Trial name
- CycliP (NCT06392438)
- Testing
- CycloSPORINE Ophthalmic, Intense Pulsed Light
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Université de Sherbrooke
Dry Eye
Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Dry Eye
To explore the law of changes in ocular surface inflammation when 0.05% cyclosporine eye drops (II) is used to treat dry eye, 50 cases of mild to moderate dry eyes were included.
- Trial name
- NCT05131152
- Testing
- Cyclosporine, oculus keratograph, in vivo laser confocal microscopy, Functional slit lamp biomicroscopy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission
This phase II trial studies how well reduced intensity donor peripheral blood stem cell (PBSC) transplant works in treating patients with de novo or secondary acute myeloid leukemia (AML) in remission.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT00045435
- Testing
- nonmyeloablative allogeneic hematopoietic stem cell transplantation, fludarabine phosphate, total-body irradiation
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Fred Hutchinson Cancer Center
Renal Transplant Patients at High-risk for Skin Cancer
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Transplant recipients have a high risk to develop skin malignancies. This effect depends on the one hand on the immunosuppressive drugs themselves and relates on the other hand on the dosage.
- Trial name
- PROSKIN (NCT01797315)
- Testing
- Sirolimus
- Volunteers
- 40 people
- Sponsor
- University Hospital of Berlin
Vogt Koyanagi Harada Disease (VKH)
Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH
The aim of this study is to evaluate the efficacy and safety of corticosteroidcombining noncorticosteroid systemic immunomodulatory therapy (NCSIT) for the treatment of Vogt Koyanagi Harada disease (VKH).
- Trial name
- NCT05120687
- Testing
- noncorticosteroid systemic immunomodulatory therapy (NCSIT)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
The Effects of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
Effect of Pharmacokinetics in Healthy Chinese Subjects
This study is a single-center, open label, self-controlled phase I clinical study, to evaluate the effects of clarithromycin or cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets in healthy Chinese…
- Trial name
- NCT06005714
- Testing
- Mindeudesivir hydrobromide tablets and Clarithromycin tablets, Mindeudesivir hydrobromide tablets and Cyclosporine softgels
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd.
Acquired Aplastic Anaemia
Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia
To assess the tolerability and efficacy of rabbit antithymocyte globulin (ATG, Thymoglobuline®) with ciclosporin (CSA) in the first line treatment of patients with acquired severe aplastic anaemia (SAA), and patients with…
- Trial name
- NCT01530555
- Testing
- Rabbit ATG, Thymoglobuline (Genzyme)
- Volunteers
- 35 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Anemia, Aplastic, Anemia, Hypoplastic
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment
Background: Severe plastic anemia can lead to problems with bone marrow platelet production and result in low blood platelet counts, which require frequent platelet transfusions to improve blood clotting.
- Trial name
- NCT00944749
- Testing
- h-ATG (ATGAM ), Cyclosporine (Gengraf )
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Graft Rejection
Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy
Everolimus is an immunosuppressive drug that is being studied for preventing acute rejection that can happen after heart transplantation. It is usually used in combination with other immunosuppressive drugs such as cyclosporine.
- Trial name
- NCT00097968
- Testing
- everolimus
- Where
- 6 sites in United States
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.